ScholarIQanswers from OpenAlex & ORCID
Nagahiro Saijo
ResearcherPublications, citations & collaboration network
Nagahiro Saijo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nagahiro Saijo have?
ScholarIQindexed works
Nagahiro Saijo has 773 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nagahiro Saijo have?
ScholarIQcitation count
Nagahiro Saijo has 45,778 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nagahiro Saijo?
ScholarIQh-index
Nagahiro Saijo has an h-index of 82 in OpenAlex.
What is the i10-index of Nagahiro Saijo?
ScholarIQi10-index
Nagahiro Saijo has an i10-index of 385 in OpenAlex.
What is the OpenAlex record for Nagahiro Saijo?
ScholarIQopenalex
The OpenAlex for Nagahiro Saijo is on the source record.
What are the most-cited papers on Nagahiro Saijo?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw, Kari Chansky, John Crowley, Ramón Rami–Porta, Hisao Asamura, Wilfried Eberhardt, Andrew G. Nicholson, Patti A. Groome, Alan Mitchell, Vanessa Bolejack, Peter Goldstraw, Ramón Rami–Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy J. Giroux, Fergus Gleeson, Patti A. Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Antoon Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan P. van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna K. Nowak, Michael Peake, Thomas W. Rice, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Nagahiro Saijo, Paul Van Schil, Jean‐Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William D. Travis, Ming‐Sound Tsao, Andrew T. Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp H. Kernstine, Hedy L. Kindler, Lee M. Krug, Kristiaan Nackaerts, Harvey I. Pass, David C. Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene H. Blackstone, F. Abad Cavaco, Emilio Ansótegui Barrera, J. Abal Arca, Isaura Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, David Ball, G.K. Bascom, Ana Isabel Blanco Orozco, M.A. González Castro, Matthew G. Blum, Domingo Chimondeguy, Vlado Cvijanović, Sebastián Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, Felipe Andreo García, Kwun M. Fong, Gloria Francisco Corral
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota, Tomohide Tamura, Kazuhiko Nakagawa, Shunichi Negoro, Yutaka Nishiwaki, Nagahiro Saijo, Y Ariyoshi, M. Fukuoka